Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Eligible Subjects With CSU Who Have Participated in CLOU064A2201

Next Previous
Search
Trial Profile

An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Eligible Subjects With CSU Who Have Participated in CLOU064A2201

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remibrutinib (Primary)
  • Indications Chronic urticaria
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 18 Apr 2024 Results assessing serum immunoglobulin (Ig) levels in NCT03926611 and NCT04109313, presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 12 Mar 2024 Results exploring the effect of remibrutinib treatment on rescue medication use in the absence of background H1 antihistamine (H1-AH) use in patients with chronic spontaneous urticaria , presented at the American Academy of Dermatology annual Meeting 2024
    • 12 Mar 2024 Results of subgroup analysis assessing Time to first relapse during treatment-free follow-up without remibrutinib , presented at the American Academy of Dermatology annual Meeting 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top